



160.

0410

01-23-2001

Patent Application
Attorney Docket No. PC10721ATMC

#2

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this 20th day of March 2001.

By

Kelley D. Surprenant
(Signature of person mailing)
Kelley D. Surprenant

RECEIVED

(Typed or printed name of person)

MAY 22 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

IN RE APPLICATION OF: Judith L. Treadway :

APPLICATION NO.: 09/767,633 : Examiner: To be assigned

FILING DATE: January 23, 2001 : Group Art Unit: To be assigned

TITLE: Methods of Treating Diabetic Cardiomyopathy Using :
Glycogen Phosphorylase InhibitorsCommissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references, cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.204(a).

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

No fee is believed to be due. However, should a fee be deemed required, the Commissioner is hereby authorized to charge any fees in connection with this paper to Deposit Account No. 16-1445.

Date: 3/20/2001

Respectfully submitted,

*Todd M. Crissey*Todd M. Crissey
Attorney for Applicant(s)
Reg. No. 37,807Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4331